My Mother Had Alzheimer's. That's Why I Started a GLP-1 at 48.

As an endocrinologist, I spend every day discussing GLP-1 medications with my patients.

This week, I became one of them.

My decision wasn't about weight loss. In fact, if anything, I would prefer not to lose weight. I'm 48 years old, I'm comfortable where I am, and I know that losing too much weight, particularly in my face, would not be something I'd welcome.

The reason I decided to start a GLP-1 is much more personal.

My mother developed subtle memory problems in her early sixties. As a physician, I recognized the signs of mild cognitive impairment before many others did. I’ll never forget sobbing one morning as I prepared to round on patients during residency – my mother had forgotten my birthday. Over the next decade, I watched Alzheimer's disease slowly take away the brilliant woman who was my best friend in the world. She ultimately died at age 74 with end-stage dementia.

Watching that progression was the most heartbreaking experience of my life. My father and I lived through every stage together, from the first moments of uncertainty to the devastating realization that the woman we both adored was gradually disappearing. We watched Alzheimer's steal her memory, her independence, her personality, and eventually her ability to recognize us. It wasn't just my mother who suffered. The disease consumed our entire family.

That experience fundamentally changed the way I think about prevention. I have an amazing husband and four wonderful children, and if there is even a possibility that I can reduce the chance that they will someday have to endure what my father and I experienced, I feel compelled to explore it. I fully recognize that this decision is based on evolving science rather than definitive proof, but I also know that waiting twenty years for perfect data is a luxury that many of us with a strong family history simply don't feel we have.

So why start a GLP-1?

The honest answer is that I don't know whether it will help. No one does. There are currently no data showing that GLP-1 medications prevent Alzheimer's disease, and there are certainly no data proving that Foundayo is better than any other GLP-1. But when I look at the totality of the science, I see a treatment that has a remarkably plausible physiological rationale and an expanding list of benefits across multiple organ systems.

Researchers have identified GLP-1 receptors throughout the brain. In laboratory studies, activation of these receptors appears to reduce neuroinflammation, improve insulin signaling within the brain, support mitochondrial function, strengthen the blood-brain barrier, improve cerebral blood flow, and reduce accumulation of amyloid-beta and tau proteins. None of this proves that GLP-1 medications prevent dementia in humans, but it does provide a compelling scientific foundation for asking the question.

Human studies are also encouraging. Large observational studies have consistently shown that people with diabetes who take GLP-1 receptor agonists develop dementia less frequently than patients treated with many other diabetes medications. These studies cannot prove cause and effect because healthier patients may be more likely to receive GLP-1 therapy in the first place, but the findings have been surprisingly consistent across multiple populations.

Randomized clinical trials are beginning to emerge. Some have shown encouraging signals, including slower brain atrophy, while others have not demonstrated significant cognitive benefits in patients who already have early Alzheimer's disease. That doesn't necessarily mean these medications won't work. It may simply mean that preventing Alzheimer's decades before symptoms develop is very different from treating established disease.

One of the reasons I chose Foundayo specifically is that it isn't a peptide at all. Unlike semaglutide or tirzepatide, which are large peptide molecules weighing over 4,000 Daltons, Foundayo is a true small molecule weighing about 883 Daltons, making it roughly five times smaller. That small size is one reason it can be taken as a simple oral pill without injections, fasting, or absorption enhancers. It also raises an intriguing scientific question. Small molecules often distribute into tissues differently than large peptides, including potentially into the central nervous system. Whether that translates into better penetration of the brain or greater protection against Alzheimer's disease is completely unknown, and there are no clinical data demonstrating that it does. Still, from a biological standpoint, I find the hypothesis compelling enough that it influenced my personal decision.

Even if my hypothesis ultimately proves to be wrong, I still see potential upside. GLP-1 medications have already demonstrated meaningful cardiovascular benefits, improved kidney outcomes, reduced liver fat, enhanced metabolic health, and reduced systemic inflammation. Researchers are now studying their potential role in conditions ranging from Parkinson's disease to osteoarthritis. They have evolved from weight-loss medications into drugs that appear to influence many aspects of aging and chronic disease.

Could I be wrong? Absolutely. Twenty years from now, we may learn that GLP-1 medications have little effect on dementia risk. On the other hand, we may also discover that starting them decades before symptoms appear was the key. Unfortunately, none of us has the luxury of waiting twenty years before making decisions about our own health.

For me, the potential benefits outweigh the risks. That doesn't mean everyone should make the same choice. This is a deeply personal decision based on my family history, my own risk tolerance, and my interpretation of an evolving body of scientific evidence. In the meantime, I'll continue prioritizing protein, lifting weights, and doing everything I can to preserve muscle while hoping that, years from now, I'll discover that this decision was one of the better bets I ever made.